ECSP13013047A - Nuevos derivados de imidazol útiles para el tratamiento de artritis - Google Patents

Nuevos derivados de imidazol útiles para el tratamiento de artritis

Info

Publication number
ECSP13013047A
ECSP13013047A ECSP13013047A ECSP13013047A EC SP13013047 A ECSP13013047 A EC SP13013047A EC SP13013047 A ECSP13013047 A EC SP13013047A EC SP13013047 A ECSP13013047 A EC SP13013047A
Authority
EC
Ecuador
Prior art keywords
arthritis
treatment
derivatives useful
imidazol derivatives
new
Prior art date
Application number
Other languages
English (en)
Inventor
Bryan Hurst Norman
Norman Earle Hughes
Timothy Andrew Woods
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP13013047A publication Critical patent/ECSP13013047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se refiere a compuestos de la fórmula siguiente:donde A, X y R1-R6 son como se describen en la presente, una sal farmacéutica del mismo, y una composición farmacéutica que contiene este compuesto; métodos para tratar dolor asociado con osteoartritis usando uno de los compuestos o una sal
ECSP13013047 2011-05-26 2013-11-25 Nuevos derivados de imidazol útiles para el tratamiento de artritis ECSP13013047A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490222P 2011-05-26 2011-05-26

Publications (1)

Publication Number Publication Date
ECSP13013047A true ECSP13013047A (es) 2014-01-31

Family

ID=46148987

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013047 ECSP13013047A (es) 2011-05-26 2013-11-25 Nuevos derivados de imidazol útiles para el tratamiento de artritis

Country Status (22)

Country Link
US (1) US8648200B2 (es)
EP (1) EP2714679A1 (es)
JP (1) JP2014518886A (es)
KR (1) KR20130143138A (es)
CN (1) CN103562200A (es)
AR (1) AR086254A1 (es)
AU (1) AU2012259234A1 (es)
BR (1) BR112013029692A2 (es)
CA (1) CA2836240A1 (es)
CO (1) CO6811858A2 (es)
CR (1) CR20130534A (es)
DO (1) DOP2013000276A (es)
EA (1) EA201391568A1 (es)
EC (1) ECSP13013047A (es)
IL (1) IL229318A0 (es)
MA (1) MA35128B1 (es)
MX (1) MX2013013859A (es)
SG (1) SG195020A1 (es)
TN (1) TN2013000434A1 (es)
TW (1) TW201311658A (es)
WO (1) WO2012161965A1 (es)
ZA (1) ZA201308609B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871947B2 (en) 2013-02-04 2014-10-28 KingChem LLC Preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ester
CN103467379A (zh) * 2013-08-23 2013-12-25 江苏恒安化工有限公司 3-三氟甲基-1-甲基吡唑-4-甲酸的制备方法
CN103483250B (zh) * 2013-10-08 2015-07-22 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN104379551B (zh) 2013-12-09 2017-03-08 金凯有限责任公司 3‑二氟甲基‑1‑甲基‑1h‑吡唑‑4‑羧酸烷基酯及其类似物的制备方法
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ２−（アシルアミノ）イミダゾールを含む組成物および方法
RU2681537C2 (ru) 2014-04-14 2019-03-07 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
BR112018001809A2 (pt) * 2015-08-17 2018-09-18 Japan Tobacco, Inc. composto de hidroxitriazina e uso médico do mesmo
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
CN109293567A (zh) * 2018-11-23 2019-02-01 上海睿腾医药科技有限公司 一种5-溴-2-甲基烟酸乙酯的合成方法
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
AU2020365113A1 (en) 2019-10-18 2022-04-07 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
CA3165735A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
US20230039553A1 (en) 2020-05-01 2023-02-09 Gilead Sciences, Inc. Cd73 compounds
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439360B2 (en) * 2004-10-15 2008-10-21 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8084466B2 (en) * 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
WO2009103778A1 (en) 2008-02-19 2009-08-27 Novasaid Ab Compounds and methods
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010127152A2 (en) 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
JP5579862B2 (ja) * 2009-10-23 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター
AR084174A1 (es) * 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica

Also Published As

Publication number Publication date
CO6811858A2 (es) 2013-12-16
AU2012259234A1 (en) 2013-11-14
IL229318A0 (en) 2014-01-30
JP2014518886A (ja) 2014-08-07
SG195020A1 (en) 2013-12-30
CR20130534A (es) 2014-03-12
AR086254A1 (es) 2013-11-27
US8648200B2 (en) 2014-02-11
MA35128B1 (fr) 2014-05-02
ZA201308609B (en) 2015-05-27
DOP2013000276A (es) 2014-03-31
KR20130143138A (ko) 2013-12-30
MX2013013859A (es) 2014-05-28
WO2012161965A1 (en) 2012-11-29
BR112013029692A2 (pt) 2017-01-17
TN2013000434A1 (en) 2015-03-30
EP2714679A1 (en) 2014-04-09
US20120302608A1 (en) 2012-11-29
EA201391568A1 (ru) 2014-04-30
TW201311658A (zh) 2013-03-16
CN103562200A (zh) 2014-02-05
CA2836240A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
ECSP13013047A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CR20140301A (es) Derivados de betulina
DOP2017000278A (es) Piridinas sustituidas y método de uso
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
CO6801794A2 (es) Derivados de isoxazolina en el tratamiento de ectoparasitos y su proceso de producción
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
SV2011003997A (es) Pirimidinas fusionadas
CR20110264A (es) Pirazolilaminopiridinas como inhibidores de fak
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CR20150171A (es) Benzamidas
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201590656A1 (ru) Азаиндолины
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides
BR112016007646A2 (pt) forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe